0.9429

4.20% -0.0413

After Hours: .95 0.0071 +0.75%

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $0.9429, with a volume of 365.41K. It is down -4.20% in the last 24 hours and up +6.19% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$0.9842

Open:

$0.98

24h Volume:

365.41K

Relative Volume:

0.68

Market Cap:

$74.91M

Revenue:

$20.60M

Net Income/Loss:

$-8.61M

P/E Ratio:

-6.8277

EPS:

-0.1381

Net Cash Flow:

$-5.28M

1W Performance:

-4.35%

1M Performance:

+6.19%

6M Performance:

+49.43%

1Y Performance:

-2.70%

1-Day Range:

$0.93

$0.9999

1-Week Range:

$0.93

$1.03

52-Week Range:

$0.565

$1.31

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2026-05-21

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	0.9429	78.19M	20.60M	-8.61M	-5.28M	-0.1381
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

May 05, 2026

MSN Money - MSN

May 05, 2026

May 02, 2026

SCYX (SCYNEXIS) posts 87.3 percent Q4 2025 EPS beat, while shares dip slightly in today’s trading. - Newser

May 02, 2026

May 01, 2026

Scynexis Ongoing Deadline Alert - TMX Newsfile

May 01, 2026

SCYNEXIS (SCYX) registers 87M shares for resale after private placement - Stock Titan

May 01, 2026

Scynexis Shareholder Alert - TMX Newsfile

May 01, 2026

SCYX Forecast, Price Target & Analyst Ratings | SCYNEXIS INC (NASDAQ:SCYX) - ChartMill

May 01, 2026

Apr 30, 2026

SCYNEXIS (NASDAQ: SCYX) seeks approval for equity plan boost and higher authorized shares - Stock Titan

Apr 30, 2026

SCYX SCYNEXIS Inc. reports 87.3 percent Q4 2025 EPS beat, shares climb 5.71 percent in today’s trading. - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 20, 2026

SCYNEXIS (NASDAQ: SCYX) seeks shareholder votes on plan increase and authorized shares - Stock Titan

Apr 20, 2026

SCYNEXIS Director Steven Gilman Announces Board Retirement - TipRanks

Apr 20, 2026

Steven C. Gilman to Retire from SCYNEXIS Board at 2026 Annual Meeting - TradingView

Apr 20, 2026

Director Steven Gilman to retire from SCYNEXIS (NASDAQ: SCYX) Board - Stock Titan

Apr 20, 2026

SCYNEXIS, Inc. Announces Retirement of Director Steven C. Gilman - marketscreener.com

Apr 20, 2026

Apr 18, 2026

SCYNEXIS (SCYX) Stock: Distribution Signals (Spikes) 2026-04-18Viral Momentum Stocks - Xã Thanh Hà

Apr 18, 2026

Apr 17, 2026

SCYNEXIS (NASDAQ: SCYX) asks shareholders to approve 1-for-5–1-for-10 reverse split - Stock Titan

Apr 17, 2026

Apr 15, 2026

Squadron Capital Management LLC Acquires 7,608,695 Shares in SCY - GuruFocus

Apr 15, 2026

Apr 13, 2026

Ideas Watch: Is SCYNEXIS Inc benefiting from innovation trendsGap Down & Real-Time Buy Zone Alerts - baoquankhu1.vn

Apr 13, 2026

SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals - ChartMill

Apr 13, 2026

Aug Patterns: Is SCYNEXIS Inc stock trending bullish2026 Reactions & High Win Rate Trade Tips - baoquankhu1.vn

Apr 13, 2026

Apr 08, 2026

Squadron Fund holds 9.6% of SCYNEXIS (NASDAQ: SCYX) - Stock Titan

Apr 08, 2026

Apr 07, 2026

Great Point Partners (SCYX) reports 9.99% ownership, joint filing details - Stock Titan

Apr 07, 2026

United StatesMintz Advises On SCYNEXIS’ Up To $92.2 Million Private Placement - Mondaq

Apr 07, 2026

Apr 02, 2026

Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia

Apr 02, 2026

Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com

Apr 02, 2026

SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan

Apr 02, 2026

Apr 01, 2026